Translational research in nicotine dependence

Jill R. Turner, Allison Gold, Robert Schnoll, Julie A. Blendy

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Nicotine addiction accounts for 4.9 million deaths each year. Furthermore, although smoking represents a significant health burden in the United States, at present there are only three FDA-approved pharmacotherapies currently on the market: (1) nicotine replacement therapy, (2) bupropion, and (3) varenicline. Despite this obvious gap in the market, the complexity of nicotine addiction in addition to the increasing cost of drug development makes targeted drug development prohibitive. Furthermore, using combinations of mouse and human studies, additional treatments could be developed from off-the-shelf, currently approved medication lists. This article reviews translational studies targeting manipulations of the cholinergic system as a viable therapeutic target for nicotine addiction.

Original languageEnglish
Article numbera012153
JournalCold Spring Harbor perspectives in medicine
Issue number3
StatePublished - Mar 2013

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology


Dive into the research topics of 'Translational research in nicotine dependence'. Together they form a unique fingerprint.

Cite this